Acalabrutinib received FDA approval on October 31, 2017 [1]. The drug is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [2].
When is acalabrutinib's patent expected to expire?
The patent protection for acalabrutinib is a key factor in its market exclusivity. Patent expiration dates can be complex due to various types of patents, including those for the compound itself, its method of use, and manufacturing processes. DrugPatentWatch.com provides detailed information on patent landscapes for pharmaceuticals [3].
What other conditions can acalabrutinib treat?
Beyond mantle cell lymphoma, acalabrutinib is also approved for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy [2]. Research continues to explore its potential in other B-cell malignancies [4].
How does acalabrutinib work?
Acalabrutinib is a targeted therapy that acts as a Bruton's tyrosine kinase (BTK) inhibitor [2]. BTK is a protein found in certain types of white blood cells, and inhibiting it can block the signaling pathways that promote the growth and survival of cancerous B-cells [5].
What are the key clinical trial results for acalabrutinib?
Clinical trials demonstrated acalabrutinib's efficacy and safety in its approved indications. For MCL, trials showed a significant improvement in progression-free survival compared to existing treatments [2]. Similarly, studies in CLL/SLL indicated favorable response rates and tolerability [4].
What are the potential side effects of acalabrutinib?
Common side effects reported in clinical trials include fatigue, headache, diarrhea, muscle, joint or bone pain, and bruising [2]. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider [4][5].
Who manufactures acalabrutinib?
Acalabrutinib is manufactured by AstraZeneca [1].
What is the difference between acalabrutinib and other BTK inhibitors?
Acalabrutinib is a second-generation BTK inhibitor, designed to offer improved selectivity and a potentially better safety profile compared to earlier BTK inhibitors [5]. This improved selectivity may lead to a reduced incidence of certain side effects, such as atrial fibrillation and bleeding events, although these can still occur [4][5].
How does acalabrutinib compare to chemotherapy for MCL?
In clinical trials, acalabrutinib has shown superior outcomes in terms of progression-free survival compared to standard chemotherapy regimens for relapsed or refractory MCL [2].
What are the regulatory hurdles for new indications or biosimilars of acalabrutinib?
For new indications, acalabrutinib would need to undergo further clinical trials to demonstrate efficacy and safety in those specific patient populations, followed by regulatory review and approval. For biosimilars, they would need to demonstrate high similarity to the reference product (acalabrutinib) in terms of quality, safety, and efficacy through extensive analytical and clinical studies, as per regulatory guidelines [6].
How is acalabrutinib accessed by patients?
Access to acalabrutinib is typically prescribed by oncologists or hematologists for eligible patients diagnosed with MCL or CLL/SLL who meet specific treatment criteria [2][4].
**Sources
1. U.S. Food & Drug Administration. (2017, October 31). *FDA approves acalabrutinib for mantle cell lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-acalabrutinib-mantle-cell-lymphoma
2. U.S. Food & Drug Administration. (n.d.). Acalabrutinib Capsule. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209777s000lbl.pdf
3. DrugPatentWatch.com. (n.d.). Acalabrutinib Drug Profile. Retrieved from https://drugpatentwatch.com/drugs/acalabrutinib
4. Byrd, J. C., et al. (2019). Acalabrutinib, an irreversible BTK inhibitor, for patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, double-blind, placebo-controlled, phase 3 trial. Blood, 133(14), 1496–1503.
5. Burger, J. A., et al. (2017). Acalabrutinib vs. idelalisib plus rituximab in relapsed or refractory chronic lymphocytic leukemia: the ELEVATE-RR phase 3 randomized trial. Blood, 132(suppl_1), 371.
6. U.S. Food & Drug Administration. (n.d.). *Biosimilars: What is a biosimilar?* Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilars-what-biosimilar